malabsorption

(redirected from fat malabsorption)
Also found in: Dictionary, Medical, Wikipedia.
  • noun

Words related to malabsorption

abnormal absorption of nutrients from the digestive tract

References in periodicals archive ?
The degree of fat restriction depends upon the severity of fat malabsorption.
Breath analysis systems are currently being sold to address a number of diagnostic testing challenges, including bacterial overgrowth testing, measurement of intestinal transit time, urinary tract infections, carbohydrate absorption, and various gastrointestinal diagnostic applications, such as fat malabsorption, gastric emptying, lactose intolerance, amino acid oxidation, liver function, fatty acid oxidation and metabolic turnover.
He found that an endopeptidase isolated from barley reduced fat malabsorption in patients with celiac disease in remission.
The majority of CF patients have pancreatic exocrine insufficiency, even in early infancy, which, if untreated, leads to fat malabsorption and malnutrition (5).
Supplementation with medium-chain triglycerides reduces HIV-associated intestinal dysfunction and fat malabsorption.
In Crohn's disease fat malabsorption occurs, allowing calcium to bind to fatty acids, leaving oxalate unbound for passage to the colon where it gets both absorbed and excreted.
These kits aid in the diagnosis of ulcers, diabetes and insulin resistance, fat malabsorption, small bowel bacterial overgrowth, and lactose intolerance.
This is common in patients with excessive absorption of dietary oxalate and in patients with fat malabsorption due to underlying enteric diseases such as IBD, or cystic fibrosis.
There was no evidence for fat malabsorption, malnutrition, or cachexia, making a secondary cause unlikely.
Supplementary clinical studies have started on Exinalda[TM] for the treatment of patients with fat malabsorption due to pancreatic insufficiency
Several reports (4,7, 8-10) have described patients with a progressive spinocerebellar syndrome associated with very low serum VE in the absence of fat malabsorption or a-[beta]-lipoproteinemia.
The primary endpoint will be the efficacy of ALTU-135 in the treatment of fat malabsorption in cystic fibrosis patients with pancreatic insufficiency through the measurement of coefficient of fat absorption (CFA).
They can be used to measure gastric emptying rate of solids (1), detect fat malabsorption (2), and evaluate pancreatic lipase activity (3), exocrine pancreatic insufficiency (4), glucose adsorption and utilization (5), liver function control (6), and lactase deficiency (7) with appropriate [sup.